| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 01/27/2000 | WO2000004046A2 Multiple splice variants of the mu-opioid receptor gene |
| 01/27/2000 | WO2000004045A1 Axor10, a g-protein coupled receptor |
| 01/27/2000 | WO2000004044A1 Glycopeptide antibiotics, combinatorial libraries of glycopeptide antibiotics and methods of producing same |
| 01/27/2000 | WO2000004043A1 Protease susceptibility ii |
| 01/27/2000 | WO2000004042A1 Peptide compounds |
| 01/27/2000 | WO2000004041A2 Methods and molecules relating to cd39-like polypeptides |
| 01/27/2000 | WO2000004033A1 Calcium (3s) tetrahydro-3-furanyl(1s,2r)-3-[[(4-aminophenyl) sulfonyl] (isobutyl) amino] -1-benzyl-2- (phosphonooxy) propylcarbamate |
| 01/27/2000 | WO2000004013A1 Antagonists of gonadotropin releasing hormone |
| 01/27/2000 | WO2000003743A2 Use of inhibitors of prenyltransferases for inhibiting fungal growth |
| 01/27/2000 | WO2000003733A1 Methods and compositions for cancer treatment |
| 01/27/2000 | WO2000003732A1 Use of inactivated immunosuppressive and/or angiogenic immunogenic proteins, preparation method and pharmaceutical or vaccine uses |
| 01/27/2000 | WO2000003729A1 Use of bromelain proteases for inhibiting blood coagulation |
| 01/27/2000 | WO2000003728A1 Chemokines as adjuvants of immune response |
| 01/27/2000 | WO2000003726A1 Lysine binding fragments of angiostatin |
| 01/27/2000 | WO2000003722A1 Nocathiacin antibiotics |
| 01/27/2000 | WO2000003721A1 Immunosupportive drug sparing diet |
| 01/27/2000 | WO2000003716A1 Topical compositions comprising an opioid analgesic and an nmda antagonist |
| 01/27/2000 | WO2000003696A1 Enteric coated pharmaceutical tablet and method of manufacturing |
| 01/27/2000 | WO2000003685A2 Nitrilase homologs |
| 01/27/2000 | WO1999064604A3 Attenuated pestiviruses |
| 01/27/2000 | WO1999063938A3 Composition and method for prevention and treatment of cardiopulmonary and renal failure or damage associated with ischemia, endotoxin release, ards or brought about by administration of certain drugs |
| 01/27/2000 | WO1999063930A3 Novel angiotensin receptor modulators and their uses |
| 01/27/2000 | WO1999061595A3 Adeno-associated viral vector-mediated expression of factor viii activity |
| 01/27/2000 | WO1999061064A8 Mammalian genes encoding 3'-5' exonuclease |
| 01/27/2000 | WO1999061040A3 USE OF α1β1 INTEGRIN RECEPTOR INHIBITORS AND TGF-β1 INHIBITORS IN THE TREATMENT OF KIDNEY DISEASE |
| 01/27/2000 | WO1999060127A3 Il-17 homologous polypeptides and therapeutic uses thereof |
| 01/27/2000 | WO1999059609A3 Use of hmg proteins for the preparation of medicaments having cytotoxic activity |
| 01/27/2000 | WO1999058564B1 Frameshift mutants of beta-amyloid precursor protein and ubiquitin-b and their use |
| 01/27/2000 | WO1999057278A3 IMMUNIZATION AGAINST AND TREATMENT FOR INFECTION BY $i(H.PYLORI) |
| 01/27/2000 | WO1999054465A9 Gene encoding syntaxin interacting protein |
| 01/27/2000 | WO1999053959A3 Use of viral vectors for treatment of the injured peripheral and central nervous system |
| 01/27/2000 | WO1999052925A9 Programmed cell death and caspase-12 |
| 01/27/2000 | WO1999050303A3 Immune response modulator alpha-2 macroglobulin complex |
| 01/27/2000 | WO1999047152A3 Use of dipeptidyl peptidase (dpp4) of fibroblast activating protein alpha for suppressing the malignant phenotype of cancer cells |
| 01/27/2000 | WO1999045128A3 Chimeric proteins with cell-targeting specificity and apoptosis-dinducing activities |
| 01/27/2000 | WO1998046257A8 Compositions comprising conjugates of stable, active, human ob protein with antibody fc chain and methods |
| 01/27/2000 | DE19831043A1 Hemmung von Alopezie Inhibition of alopecia |
| 01/27/2000 | DE19828114A1 Produgs instabiler Inhibitoren der Dipeptidyl Peptidase IV Prodrugs unstable inhibitors of dipeptidyl peptidase IV |
| 01/27/2000 | CA2337635A1 Method of making proteins in transformed yeast cells |
| 01/27/2000 | CA2337511A1 Peptides of il-2 and derivatives thereof and their use as therapeutic agents |
| 01/27/2000 | CA2337407A1 Antagonists of gonadotropin releasing hormone |
| 01/27/2000 | CA2337398A1 Nocathiacin antibiotics |
| 01/27/2000 | CA2337362A1 Cloning and characterisation of novel mammalian peptidases |
| 01/27/2000 | CA2337231A1 Lysine binding fragments of angiostatin |
| 01/27/2000 | CA2337103A1 Glycopeptide antibiotics, combinatorial libraries of glycopeptide antibiotics and methods of producing same |
| 01/27/2000 | CA2335381A1 Use of inhibitors of prenyltransferases for inhibiting fungal growth |
| 01/27/2000 | CA2335315A1 Nitrilase homologs |
| 01/27/2000 | CA2335277A1 Multiple splice variants of the mu-opioid receptor gene |
| 01/27/2000 | CA2335274A1 Tissue factor protein variants with increased affinity for coagulation factor fvii/fviia |
| 01/27/2000 | CA2335099A1 New caspase homologue |
| 01/27/2000 | CA2335096A1 Methods and materials relating to novel cd39-like polypeptides |
| 01/27/2000 | CA2334161A1 Use of nucleic acid molecules as antiviral agents |
| 01/27/2000 | CA2334075A1 Bone morphogenic protein |
| 01/27/2000 | CA2334038A1 Compositions and methods for therapy and diagnosis of prostate cancer |
| 01/27/2000 | CA2333929A1 Soluble derivatives of anti-angiogenic peptides |
| 01/27/2000 | CA2333910A1 Neurotrophic growth factor |
| 01/27/2000 | CA2333895A1 Snurportin i human m3g-cap specific nucleus import receptor protein with new domain structure, the production and use thereof |
| 01/27/2000 | CA2333853A1 Mucins |
| 01/27/2000 | CA2333467A1 Human presenilin-associated protein |
| 01/27/2000 | CA2332634A1 Repression of cell transformation with human pea3 |
| 01/27/2000 | CA2303062A1 Human aspartic proteases |
| 01/26/2000 | EP0974664A2 Human polypeptides and polynucleotides homolog to mouse testes-specific angiotensins converting enzyme |
| 01/26/2000 | EP0974663A1 Lipoprotein associated phospholipase A2, inhibitors thereof and use of same in diagnosis and therapy |
| 01/26/2000 | EP0974659A2 Viral nucleotide sequences |
| 01/26/2000 | EP0974655A2 G-CSF analog compositions and methods |
| 01/26/2000 | EP0974653A2 Human gastric cancer antigen gene and protein |
| 01/26/2000 | EP0974651A1 Physiologically active protein originating in mammals |
| 01/26/2000 | EP0974650A1 Endothelial cell growth inhibitors |
| 01/26/2000 | EP0974599A1 Recombinant single-stranded equine chorionic gonadotropin |
| 01/26/2000 | EP0974360A2 Pharmaceutical preparations for use in combatting or preventing surface infections caused by microorganisms |
| 01/26/2000 | EP0974359A2 FSH and FSH variant formulations, products and methods |
| 01/26/2000 | EP0974358A2 Orally-administrable therapeutic and/or prophylactic agent for HTLV-1-related diseases |
| 01/26/2000 | EP0974357A1 Chemokines as adjuvants of immune response |
| 01/26/2000 | EP0974344A2 Composition and pharmaceutical dosage form for colonic drug delivery using polysaccharides |
| 01/26/2000 | EP0974058A2 20 human secreted proteins |
| 01/26/2000 | EP0973942A2 Screening method for proline-rich proteins |
| 01/26/2000 | EP0973934A1 Transgenically produced non-secreted proteins |
| 01/26/2000 | EP0973933A1 Immunological tolerance to hiv epitopes |
| 01/26/2000 | EP0973926A1 Adenoviral vectors with modified tropism |
| 01/26/2000 | EP0973916A1 Composition and method for inducing an immune response against tumour-related antigens |
| 01/26/2000 | EP0973914A1 Proteins having lecithin-cholesterol acyltransferase-like activity, their production and use |
| 01/26/2000 | EP0973904A1 COMPOSITIONS AND USE OF M-CSF-alpha |
| 01/26/2000 | EP0973903A2 Protein for inhibiting apoptosis |
| 01/26/2000 | EP0973902A1 Radioisotope concentrator methods and compositions |
| 01/26/2000 | EP0973901A2 Flip gene and flip protein |
| 01/26/2000 | EP0973900A1 flt3 LIGAND CHIMERIC PROTEINS |
| 01/26/2000 | EP0973897A1 Human tumor-associated membrane protein |
| 01/26/2000 | EP0973895A1 Transcription factor islet-brain 1 (ib1) |
| 01/26/2000 | EP0973894A1 Renal nuclear matrix proteins, polynucleotide sequences encoding them, and their use |
| 01/26/2000 | EP0973893A1 Intracellular amyloid-beta binding (erab) polypeptide |
| 01/26/2000 | EP0973892A2 28 human secreted proteins |
| 01/26/2000 | EP0973891A1 Human chemokine receptor-like chemokine |
| 01/26/2000 | EP0973890A2 Secreted proteins and polynucleotides encoding them |
| 01/26/2000 | EP0973888A1 Dendritic cell-derived growth factor |
| 01/26/2000 | EP0973887A1 Porcine leptin protein, nucleic acid sequences coding therefor and uses thereof |
| 01/26/2000 | EP0973881A2 Mycobacterium recombinant vaccines |
| 01/26/2000 | EP0973879A2 Coxsackie virus vectors for delivery of nucleic acids encoding antigenic or therapeutic products |
| 01/26/2000 | EP0973872A1 Use of nerve growth factor for the storage, culture or treatment of cornea |
| 01/26/2000 | EP0973819A1 Non-antigenic branched polymer conjugates |
| 01/26/2000 | EP0973818A1 Biodegradable terephthalate polyester-poly(phosphate) polymers, compositions, articles, and methods for making and using the same |